Massive study tracks Long-Term effects of rare disease drug
NCT ID NCT03557060
Summary
This study monitored the long-term safety and effectiveness of NUCALA injections for people with EGPA, a rare autoimmune disease. It followed over 4,000 patients for up to two years while they received the drug in real-world settings. The goal was to collect information on side effects and how well the drug controlled the disease over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Tokyo, 107-0052, Japan
Conditions
Explore the condition pages connected to this study.